Difference between revisions of "Periampullary adenocarcinoma"

From HemOnc.org - A Hematology Oncology Wiki
Jump to navigation Jump to search
m (Text replacement - "</big>" to "")
 
(46 intermediate revisions by 3 users not shown)
Line 1: Line 1:
−
<!--'''Use of this site is subject to you reading and agreeing with the terms set forth in the [[HemOnc.org_-_A_Hematology_Oncology_Wiki:General_disclaimer|disclaimer]]. If this is your first time visiting, we suggest you read the [[tutorial]].'''-->
+
<span id="BackToTop"></span>
−
 
+
<div class="noprint" style="background-color:LightGray; position:fixed; bottom:2%; right:0.25%; padding-left:5px; padding-right:5px; margin: 15px; opacity:0.8; border-style: solid; border-color:DarkGray; border-width: 1px">
−
<!--Is there a regimen missing from this list? Would you like to share a different dosage/schedule or an additional reference for a regimen? Have you noticed an error? Do you have an idea that will help the site grow to better meet your needs and the needs of many others? You are [[How_to_contribute|invited to contribute to the site]].-->
+
[[#top|Back to Top]]
−
{| class="wikitable" style="text-align:center; width:100%;"
+
</div>
−
! colspan="2" align="center" style="color:white; font-size:125%; background-color:#08519c" |'''Section editor'''
+
{{#lst:Editorial board transclusions|giei}}
−
! colspan="2" align="center" style="color:white; font-size:125%; background-color:#08519c" |'''Page editor'''
 
−
|-
 
−
| style="background-color:#F0F0F0; width:15%" |[[File:nkv.jpg|frameless|upright=0.3|center]]
 
−
| style="width:35%" |<big>[[User:Neetavenepalli|Neeta K. Venepalli, MD, MBA]]<br>Chicago, IL</big>
 
−
| style="background-color:#F0F0F0; width:15%" |[[File:Ivy_Abraham.JPG|frameless|upright=0.3|center]]
 
−
| style="width:35%" |<big>[[User:Ivyabraham|Ivy Abraham, MD]]<br>Chicago, IL</big>
 
−
|-
 
−
|}
 
 
{| class="wikitable" style="float:right; margin-right: 5px;"
 
{| class="wikitable" style="float:right; margin-right: 5px;"
 
|-
 
|-
Line 17: Line 9:
 
<div style="background-color: #deebf6; border: 1px solid #808000; padding: 5px; {{border-radius|16px}}"><font size="4"><b>{{#ask: [[-Has subobject::{{FULLPAGENAME}}]] |?Variant |limit=10000|format=sum}} [[Tutorial#Variants|variants]] on this page</b></font></div>
 
<div style="background-color: #deebf6; border: 1px solid #808000; padding: 5px; {{border-radius|16px}}"><font size="4"><b>{{#ask: [[-Has subobject::{{FULLPAGENAME}}]] |?Variant |limit=10000|format=sum}} [[Tutorial#Variants|variants]] on this page</b></font></div>
 
|}
 
|}
 +
''Are you looking for a regimen, but can't find it here? For placebo or observational studies in this condition, please visit [[Periampullary adenocarcinoma - null regimens|this page]]. If you still can't find it, please let us know so we can add it!'' <br>
 +
Note: there is some overlap, especially in the earlier literature, between treatment regimens for periampullary adenocarcinoma and those for '''[[pancreatic cancer|pancreatic adenocarcinoma]]''', '''[[cholangiocarcinoma]]''', and '''[[gallbladder cancer]]'''; please see those pages for additional regimens.
 
{{TOC limit|limit=3}}
 
{{TOC limit|limit=3}}
−
'''Liver cancer''' or hepatobiliary cancer comprises cancers that arise within the liver and its hepatocytes (hepatocellular carcinoma) and the biliary tract cancers, which include bile duct cancer/cholangiocarcinoma and gallbladder cancer.
 
−
 
 
=Guidelines=
 
=Guidelines=
−
==[http://www.esmo.org/ ESMO]==
+
'''Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only.'''
−
*'''2016:''' [http://annonc.oxfordjournals.org/content/27/suppl_5/v28.full.pdf+html Biliary cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.] [https://www.ncbi.nlm.nih.gov/pubmed/27664259 PubMed]
+
==[https://www.esmo.org/ ESMO]==
−
 
+
*'''2016:''' [https://doi.org/10.1093/annonc/mdw324 Biliary cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.] [https://pubmed.ncbi.nlm.nih.gov/27664259/ PubMed]
−
==[https://www.nccn.org/ NCCN]==
 
−
*[https://www.nccn.org/professionals/physician_gls/pdf/hepatobiliary.pdf NCCN Guidelines - Hepatobiliary Cancers]
 
−
 
 
−
=Adjuvant therapy=
 
−
 
 
−
==Placebo==
 
−
{| class="wikitable" style="float:right; margin-left: 5px;"
 
−
|-
 
−
|[[#top|back to top]]
 
−
|}
 
−
 
 
−
===Regimen===
 
−
{| class="wikitable" style="width: 100%; text-align:center;"
 
−
!style="width: 25%"|Study
 
−
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
 
−
!style="width: 25%"|Comparator
 
−
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
 
−
|-
 
−
|[http://jamanetwork.com/journals/jama/fullarticle/1216477 Neoptolemos et al. 2012 (ESPAC-3)]
 
−
|style="background-color:#1a9851"|Phase III (C)
 
−
|1. 5-FU & Leucovorin<br> 2. Gemcitabine
 
−
|style="background-color:#ffffbf"|Seems not superior
 
−
|-
 
−
|}
 
−
====Preceding treatment====
 
−
*Surgery
 
  
−
===References===
+
==NCCN==
−
# '''ESPAC-3:''' Neoptolemos JP, Moore MJ, Cox TF, Valle JW, Palmer DH, McDonald AC, Carter R, Tebbutt NC, Dervenis C, Smith D, Glimelius B, Charnley RM, Lacaine F, Scarfe AG, Middleton MR, Anthoney A, Ghaneh P, Halloran CM, Lerch MM, Oláh A, Rawcliffe CL, Verbeke CS, Campbell F, Büchler MW; European Study Group for Pancreatic Cancer. Effect of adjuvant chemotherapy with fluorouracil plus folinic acid or gemcitabine vs observation on survival in patients with resected periampullary adenocarcinoma: the ESPAC-3 periampullary cancer randomized trial. JAMA. 2012 Jul 11;308(2):147-56. Erratum in: JAMA. 2012 Nov 14;308(18):1861. [http://jamanetwork.com/journals/jama/fullarticle/1216477 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/22782416 PubMed]
+
*[https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1511 NCCN Guidelines - Ampullary Adenocarcinoma]
 +
**'''2023:''' Chiorean et al. [https://doi.org/10.6004/Jnccn.2023.0034 Ampullary Adenocarcinoma, Version 1.2023, NCCN Clinical Practice Guidelines in Oncology.] [https://pubmed.ncbi.nlm.nih.gov/37433437/ PubMed]
  
 
[[Category:Periampullary adenocarcinoma regimens]]
 
[[Category:Periampullary adenocarcinoma regimens]]
 
[[Category:Disease-specific pages]]
 
[[Category:Disease-specific pages]]
−
[[Category:Gastrointestinal cancers]]
+
[[Category:Biliary tract cancers]]

Latest revision as of 00:28, 4 July 2024

Back to Top

Section editor
Eric Marks Headshot.jpg
 Eric I. Marks, MD
Boston University
Boston, MA, USA
0 regimens on this page
0 variants on this page

Are you looking for a regimen, but can't find it here? For placebo or observational studies in this condition, please visit this page. If you still can't find it, please let us know so we can add it!
Note: there is some overlap, especially in the earlier literature, between treatment regimens for periampullary adenocarcinoma and those for pancreatic adenocarcinoma, cholangiocarcinoma, and gallbladder cancer; please see those pages for additional regimens.


Guidelines

Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only.

ESMO

NCCN

Retrieved from "https://hemonc.org/w/index.php?title=Periampullary_adenocarcinoma&oldid=88238"